IDEVvsXBI
iShares Core MSCI International Developed Markets ETF against SPDR S&P Biotech ETF — the fee, the flows, the book, and a year head-to-head.
Head to head
| IDEV | XBI | |
|---|---|---|
| Expense ratio | 0.040% | 0.35% |
| Assets | $32.4B | $10.3B |
| Net flow, 1 month | +$828M | −$567M |
| Net flow, 1 year | +$6.8B | +$935M |
| Return, YTD | +8.9% | +23.8% |
| Return, 1 year | +10.0% | +45.6% |
| Avg daily volume | 2.6M | 8.9M |
| Holdings | 2281 | 135 |
| Listed | Mar 21, 2017 | Jan 31, 2006 |
| Options market | Yes | Yes |
MARKED CELLS LEAD ON THAT LINE · LOWER FEE, LARGER ASSETS, STRONGER FLOWS & RETURNS